吉非替尼治疗化疗失败的晚期非小细胞肺癌临床观察  

Clinical observation on treatment with gefitinib in advanced non-small cell lung cancer patients failed to previous chemotherapy

作　　者：马锐[1] 

机构地区：[1]辽宁省肿瘤医院,辽宁沈阳110042

出　　处：《现代肿瘤医学》2011年第4期697-699,共3页Journal of Modern Oncology

摘　　要：目的:评价吉非替尼治疗化疗失败的晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:对68例化疗失败的经病理或细胞学证实的晚期NSCLC患者给予吉非替尼250mg,qd,口服,至病情进展或出现不可耐受的不良反应。结果:68例患者中,CR 1例,PR 20例,SD 23例,PD 24例。有效率30.88%(21/68),疾病控制率为64.71%(44/68);全组中位疾病进展时间(TTP)为5.2个月,中位生存时间为9.3个月,1年生存率为52.94%(36/68)。与药物相关的不良反应主要为Ⅰ、Ⅱ度皮疹和腹泻,皮疹发生率为26.47%(18/68),腹泻发生率为19.12%(13/68),多在用药后1周内出现,症状轻不需特殊处理。1例出现Ⅰ度转氨酶升高。结论:吉非替尼治疗化疗失败的晚期非小细胞肺癌安全有效,不良反应轻微,患者耐受性和依从性良好。Objective：To evaluate the efficacy and toxicity of gefitinib in treatment of patients with non-small cell lung cancer（NSCLC）who failed to previous chemotherapy.Methods：Total of 68 failed to previous chemotherapy patients with advanced NSCLC confirmed by pathology or cytology were treated with oral gefitinib 250 mg/d until disease progression,or intolerated toxicity.Results：Of 68 patients,one patient achieved complete remission,20 patients achieved partial response,23 achieved stable disease and 24 had progressive disease.Response rate was 30.88%（21/68） disease control rate 64.71%（44/68）median time to progression 5.2 months,median overall survival 9.3 months,1-year survival rate 52.94%（36/68）.Drug-related toxicity was mainly mild（1 or 2 grade） skin reactions and diarrhea.skin reactions occurred in 26.47% of patients（18/68）,diarrhea occurred in 19.12% of patients（13/68）,symptoms more appeared in a week after administration,and could relieve without any special treatment,1 patient happened mild transaminase elevation.Conclusion：Gefitinib is effiectire and safe to advanced NSCLC failed to previous chemotherapy,its drug-related toxicity was light,well tolerated.

关 键 词：吉非替尼 晚期 非小细胞肺癌 化疗失败 

分 类 号：R734.2[医药卫生—肿瘤]